These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29341822)

  • 1. Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults.
    Aggarwal A; Schrimpf L; Lauriello J
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):221-223. PubMed ID: 29341822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
    Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety evaluation of aripiprazole in bipolar disorder.
    Cuomo A; Beccarini Crescenzi B; Goracci A; Bolognesi S; Giordano N; Rossi R; Facchi E; Neal SM; Fagiolini A
    Expert Opin Drug Saf; 2019 Jun; 18(6):455-463. PubMed ID: 31072228
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
    Keramatian K; Chakrabarty T; Yatham LN
    CNS Drugs; 2019 May; 33(5):431-456. PubMed ID: 30963507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.
    Belge JB; Sabbe BGCC
    Expert Opin Pharmacother; 2024 Feb; 25(3):295-299. PubMed ID: 38465894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic.
    Tohen M; Goldberg JF; Hassoun Y; Sureddi S
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):627-636. PubMed ID: 29694243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
    Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
    Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.
    Azorin JM; Simon N
    Drugs; 2019 Oct; 79(15):1657-1677. PubMed ID: 31468317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Aripiprazole in Comorbid Bipolar Disorder and Borderline Personality Disorder and Substance Abuse.
    Martínez JS; Caballero AR
    J Clin Psychopharmacol; 2017 Apr; 37(2):266-267. PubMed ID: 28145998
    [No Abstract]   [Full Text] [Related]  

  • 14. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
    Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
    Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
    [No Abstract]   [Full Text] [Related]  

  • 15. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat the disease not the symptoms: Successful management of obsessive compulsive disorder in bipolar disorder with aripiprazole augmentation.
    Patra S
    Aust N Z J Psychiatry; 2016 Aug; 50(8):809-10. PubMed ID: 27357710
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report.
    Ballester-Gracia I; Pérez-Almarcha M; Galvez-Llompart A; Hernandez-Viadel M
    BMC Pharmacol Toxicol; 2019 Aug; 20(1):52. PubMed ID: 31462311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long-acting injection: A case report.
    Kurata T; Hashimoto T; Suzuki H
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):238-240. PubMed ID: 31325244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
    J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
    Samalin L; Boudieu L; Llorca PM
    Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.